































































Effect of Tolvaptan treatment on acid-base homeostasis in ADPKD patients





To appear in: Kidney International Reports
Received Date: 23 March 2021
Accepted Date: 5 April 2021
Please cite this article as: Bargagli M, Ferraro PM, Dhayat N, Anderegg M, Fuster D, Effect of Tolvaptan
treatment on acid-base homeostasis in ADPKD patients, Kidney International Reports (2021), doi:
https://doi.org/10.1016/j.ekir.2021.04.012.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2021 Published by Elsevier Inc. on behalf of the International Society of Nephrology.
Effect of Tolvaptan treatment on acid-base homeostasis in ADPKD patients 
 
Matteo Bargagli1, Pietro Manuel Ferraro1, Nasser Dhayat2, Manuel Anderegg2, Daniel Fuster2 
 
1U.O.C. Nefrologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del 
Sacro Cuore, Largo Agostino Gemelli 8, 00168, Roma, Italia. 
 
2Division of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, 
Freiburgstrasse 15, 3010, Bern, Switzerland 
 
Keywords: ADPKD; acid-base homeostasis 
 
Corresponding author: 
Dr. Matteo Bargagli, MD 
ORCID: 0000-0001-9288-4111 
U.O.C. Nefrologia, Fondazione Policlinico Universitario A. Gemelli IRCCS 
Università Cattolica del Sacro Cuore 
Largo Agostino Gemelli 8, 00168, Roma, Italia 
E-mail: matteo.bargagli@unicatt.it 











To the editor: 
We read with great interest the recent report of Heida et al1 on the impact of tolvaptan on acid-
base status in ADPKD patients. The authors hypothesized that V2 receptor antagonism may induce 
a state of metabolic alkalosis by activation of V1 receptors through increased circulating 
vasopressin, which in turn would stimulate renal net acid excretion (NAE). The authors found no 
changes in plasma bicarbonate after tolvaptan administration and therefore concluded that 
tolvaptan does not affect renal NAE. 
Recent studies2,3 indicate, however, that urinary citrate is superior to plasma bicarbonate for the 
detection of subtle acid-base alterations. We previously observed that ADPKD patients treated 
with tolvaptan exhibit a significant reduction in renal net acid excretion (NAE), with an increase in 
urinary citrate4. These changes were associated with increased net gastrointestinal alkali 
absorption (NGIA; a marker of alkali intake) but unaltered urinary sulfate (a marker of acid intake), 
suggesting that lower NAE may be due to higher alkali intake or gut alkali absorption in patients 
taking tolvaptan. Thus, our data suggest that tolvaptan treatment is associated with changes in 
renal NAE and hence acid-base homeostasis in ADPKD patients. The underlying mechanisms, 
however, remain to be elucidated. 
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